tiprankstipranks
Advertisement
Advertisement
Lineage Cell announces 36-month results from Phase 1/2a study of RG6501
PremiumThe FlyLineage Cell announces 36-month results from Phase 1/2a study of RG6501
27d ago
Lineage Cell Therapeutics initiated with a Buy at Canaccord
Premium
The Fly
Lineage Cell Therapeutics initiated with a Buy at Canaccord
1M ago
Lineage Cell Therapeutics announces formation of Scientific Advisory Board
Premium
The Fly
Lineage Cell Therapeutics announces formation of Scientific Advisory Board
2M ago
Lineage Cell Therapeutics Extends Runway Amid R&D Surge
PremiumCompany AnnouncementsLineage Cell Therapeutics Extends Runway Amid R&D Surge
3M ago
Regulatory Risks Loom for Lineage Cell Therapeutics as Legacy Pluripotent Cell Lines Face Potential Compliance Challenges
Premium
Company Announcements
Regulatory Risks Loom for Lineage Cell Therapeutics as Legacy Pluripotent Cell Lines Face Potential Compliance Challenges
3M ago
Lineage Cell Therapeutics reports Q4 EPS 0c vs (2c) last year
Premium
The Fly
Lineage Cell Therapeutics reports Q4 EPS 0c vs (2c) last year
3M ago
Lineage Cell Therapeutics receives iPSC line from Factor Bioscience
PremiumThe FlyLineage Cell Therapeutics receives iPSC line from Factor Bioscience
5M ago
Lineage Therap Withdraws CIRM Grant Application
Premium
Company Announcements
Lineage Therap Withdraws CIRM Grant Application
6M ago
Lineage Cell says first OpRegen development milestone under Roche pact achieved
Premium
The Fly
Lineage Cell says first OpRegen development milestone under Roche pact achieved
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100